Search Results
You are looking at 1 - 2 of 2 items for
- Author: Jiali Liu x
- Refine by access: All content x
Search for other papers by XueJing Zhang in
Google Scholar
PubMed
Search for other papers by JianHua Li in
Google Scholar
PubMed
Search for other papers by JiaLi Liu in
Google Scholar
PubMed
Search for other papers by HaoShu Luo in
Google Scholar
PubMed
Search for other papers by KeMian Gou in
Google Scholar
PubMed
Search for other papers by Sheng Cui in
Google Scholar
PubMed
Prostaglandin F2 α (PGF2 α) is a key factor in the triggering of the regression of the corpus luteum (CL). Furthermore, it has been reported that Slit/Robo signaling is involved in the regulation of luteolysis. However, the interactions between PGF2 α and Slit/Robo in the progression of luteolysis remain to be established. This study was designed to determine whether luteolysis is regulated by the interactions of PGF2 α and Slit/Robo in the mouse CL. Real-time PCR and immunohistochemistry results showed that Slit2 and its receptor Robo1 are highly and specifically co-expressed in the mouse CL. Functional studies showed that Slit/Robo participates in mouse luteolysis by enhancing cell apoptosis and upregulating caspase3 expression. Both in vitro and in vivo studies showed that PGF2 α significantly increases the expression of Slit2 and Robo1 during luteolysis through protein kinase C-dependent ERK1/2 and P38 MAPK signaling pathways, whereas an inhibitor of Slit/Robo signaling significantly decreases the stimulating effect of PGF2 α on luteolysis. These findings indicate that Slit/Robo signaling plays important roles in PGF2 α-induced luteolysis by mediating the PGF2 α signaling pathway in the CL.
Leonard Davis School of Gerontology, University of Southern California, Los Angeles, California, USA
Search for other papers by Jiali Liu in
Google Scholar
PubMed
Search for other papers by Yue Li in
Google Scholar
PubMed
Search for other papers by Xiaoyan Zhou in
Google Scholar
PubMed
Search for other papers by Xi Zhang in
Google Scholar
PubMed
Search for other papers by Hao Meng in
Google Scholar
PubMed
Search for other papers by Sanyuan Liu in
Google Scholar
PubMed
Search for other papers by Lei Zhang in
Google Scholar
PubMed
Search for other papers by Juntao He in
Google Scholar
PubMed
Search for other papers by Qian He in
Google Scholar
PubMed
Search for other papers by Yan Geng in
Google Scholar
PubMed
High-fat diet (HFD) not only induces insulin resistance in liver, but also causes autophagic imbalance and metabolic disorders, increases chronic inflammatory response and induces mitochondrial dysfunction. Calcium/calmodulin-dependent protein kinase IV (CaMKIV) has recently emerged as an important regulator of glucose metabolism and skeletal muscle insulin action. Its activation has been involved in the improvement of hepatic and adipose insulin action. But the underlying mechanism is not fully understood. In the present study, we aimed to address the direct effects of CaMKIV in vivo and to evaluate the potential interaction of impaired insulin sensitivity and autophagic disorders in hepatic insulin resistance. Our results indicated obese mice receiving CaMKIV showed decreased blood glucose and serum insulin and improved insulin sensitivity as well as increased glucose tolerance compared with vehicle injection. Meanwhile, defective hepatic autophagy activity, impaired insulin signaling, increased inflammatory response and mitochondrial dysfunction in liver tissues which are induced by high-fat diet were also effectively alleviated by injection of CaMKIV. Consistent with these results, the addition of CaMKIV to the culture medium of BNL cl.2 hepatocytes markedly restored palmitate-induced hepatic insulin resistance and autophagic imbalance. These effects were nullified by blockade of cyclic AMP response element-binding protein (CREB), indicating the causative role of CREB in action of CaMKIV. Our findings suggested that CaMKIV restores hepatic autophagic imbalance and improves impaired insulin sensitivity via phosphorylated CREB signaling pathway, which may offer novel opportunities for treatment of obesity and diabetes.